Related Experiment Video
Updated: Jan 1, 2026
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Pathological findings in central nervous system demyelination associated with infliximab
Alicja Kalinowska-Lyszczarz1, Mahboobeh Fereidan-Esfahani2, Yong Guo2
1Department of Neurology, Mayo Clinic, Rochester, MN, USA/Department of Neurology, Poznan University of Medical Sciences, Poznan, Poland.
Background:
Tumor necrosis factor alpha (TNF-alpha) inhibitors, such as infliximab, are commonly used to treat rheumatoid arthritis (RA) and other immune-mediated disorders.
Objective:
To determine whether infliximab-associated central nervous system (CNS) demyelination can be differentiated from multiple sclerosis (MS).
Methods:
We present a case of pathologically proven CNS demyelination in a patient treated with infliximab and describe clinical-radiographic-neuropathological findings. Putative mechanisms of TNF-alpha inhibitor-associated CNS demyelination are described.
Results And Conclusion:
Infliximab treatment is associated with CNS inflammatory demyelinating activity, which is histopathologically indistinguishable from MS.
More Related Videos
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...